ArticleDiscover oncology2025
ADAMTSL2 is an independent predictor for the prognosis of gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsTo explore novel biomarkers capable of predicting the prognosis of gastric cancer (GC) and investigate the mechanisms underlying the development of GC.
methodsFirstly, differentially expressed genes (DEGs) in GC tumors and adjacent tissues were analyzed using transcriptome sequencing data. Then, the DEGs significantly associated with the prognosis of GC were selected. From this subset, genes with high protein expression levels in tumor tissues were focused. Multivariate hazard analysis was performed to further identify DEGs with independent prognostic value for GC patients. Eventually, the potential mechanisms involving DEGs that underlie the development of GC were investigated.
resultsAltogether, 25 previously DEGs that have not been reported before were discovered in the context of GC. Among these genes, ADAMTSL2, DSCC1, COL5A3, F2RL2, GRIN2D, IGSF6, IER5L, PLA2G7, PODNL1, RCN3 and RTN4RL2 were significantly associated with the overall survival, first progression and post progression survival of GC patients. Moreover, protein levels of ADAMTSL2, COL5A3, DSCC1, GRIN2D, PODNL1 and RCN3 were consistently highly expressed in clinical GC specimens. Furthermore, multivariate hazard analysis identified ADAMTSL2 as an independent predictor of GC prognosis. Further exploration revealed a potential regulatory connection between ADAMTSL2 and hsa-miR-7-2-3p. hsa-miR-7-2-3p was significantly down-regulated in GC and GC patients with low expression of hsa-miR-7 had a poor overall survival. Additionally, ADAMTSL2 was significantly co-expressed with key molecules (NOTCH1, NOTCH3, NOTCH4 and HEY1) in Notch signaling pathway.
conclusionsADAMTSL2 stands out as an independent predictor for the prognosis of GC and may play a crucial pathological role in the development of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.